Identity
Merck Sharp & Dohme de España, S.A.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €152.4M | |
| 2025 | €235.1M | |
| 2024 | €79.7M | |
| + regional platforms | ||
| 2023 | €100.9M | |
| 2022 | €78.2M | |
| 2021 | €48.5M | |
| 2020 | €15.0M | |
| 2019 | €26.1M | |
| 2018 | €8.0M | |
| 2017 | €5.1M | |
| 2016 | €1.1M | |
In figures
Volume
Between 2016 and 2026 it won 1,033 contracts worth €750M on its own, with 58 buyers. Its 7 joint-venture (UTE) contracts are shown separately.
Price
In 2024–2026 its median discount was 13.1%; the middle half of its discounts between 5.7% and 25.2% (12 comparable awards).
Competition
Since 2024, 50% of its comparable value was won with a discount and against other bidders. It was the only bidder in 81% of its contracts (2016–2026).
Renewals
43 contracts (€69.4M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Merck Sharp & Dohme de España, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Merck Sharp & Dohme de España, S.A.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
2024–2026: median 13.1% · middle half between 5.7% and 25.2% · 12 awards
2019–2023: median 25.3% (9 awards) · 2024–2026: median 13.1% (12 awards).
2019–2026: median 15.2% · middle half between 4.3% and 28.9% · 21 awards
Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
By sector
Productos farmacéuticos
CPV 336
448 contracts · €465M
By buyer · 2024–2026
Servicio Murciano de Salud - Junta de Compras
Productos farmacéuticos
4 contracts · €3.93M
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
4 awards at the tender price, left out of the discounts.
How it wins
Whether it wins with or without competition.
50% of the comparable value since 2024 (€13.0M of €26.0M) was won with a discount and against other bidders. €10.0M (39%) was awarded with a discount and without other bidders.
Comparable: 31 awards with a published budget and bidder count (€26.0M of €467M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 68.0% of the value was awarded through negotiated without publicity procedure (38.2% of contracts); followed by Open (13.4%) and Based on a framework agreement (12.0%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 43 of its contracts come up for tender again, worth €69.4M.
| Expected end | Buyer | Value |
|---|---|---|
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €492k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €38.0k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €8.70k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €5.73k |
| 2026 | Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad | — |
and 38 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| Departament de Salut | 35 | 112 M | 2020–2026 |
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 12 | 81 M | 2024–2026 |
| Gerencia de Servicio Sanitarios de Fuerteventura | 293 | 79 M | 2018–2026 |
| Dirección General de Planificación Económica | 42 | 65 M | 2018–2026 |
| Consejería de Sanidad (Comunidad de Madrid) | 9 | 49 M | 2024–2026 |
and 53 more buyers
Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 1,005 contracts).
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 17/06/2026 | 2º cbam con merck sharp & dohme de españa, s.a. expte. 88/2025. am suministro de vacunas frente al … | Servicio Andaluz de Salud | 2 | €237k |
| 30/04/2026 | LOTE 18 Vacuna frente a rotavirus | Consejería de Sanidad del Gobierno de Canarias | 2 | €644k |
| 01/04/2026 | Suministro de medicamento raltegravir para hospitales Asepeyo Sant Cugat y Coslada | Subdirección General Sanitaria de ASEPEYO. Mutua Colaboradora con la Seguridad Social. num. 151 | 1 | €20.7k |
| 11/03/2026 | cordoba 5ª prorroga 7º cbam merck sharp & dohme de españa, s.a. para suministro de tracto sucesivo … | Servicio Andaluz de Salud | 1 | €52.2k |
| 02/03/2026 | 3º Contrato derivado de Acuerdo Marco, Suministro de ISENTRESS 400 MG® para los Centros Penitenciar… | Subdirección General de Planificación y Gestión Económica | 1 | €10.5k |